Webinars, Pharmaceutical

Aptar Pharma discusses intranasal administration for CNS therapeutics

CNS therapies are a well-defined target for drug repurposing for intranasal administration with a growing track record of success that includes commercialized products for treatment resistant depression and seizures.

This webinar examines the defining benefits of intranasal administration such as high patient acceptability, rapid onset, and the ability to deliver drugs to unconscious patients. The biology of drug delivery for CNS therapeutics is also explored with reference to the benefits of bypassing the blood brain barrier. Off-the-shelf devices for intranasal administration are reviewed and strategies for reformulation – powder or liquid – are considered.

The expert support available from Aptar Pharma, to support all aspects of drug reformulation for intranasal administration, are also discussed.

Watch the webinar
Speaker(s): Dr. Julie D. Suman
25 Feb 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More

This Might Also Be of Interest

22 Apr 2021

Case Study – Pre-Clinical Respiratory Research with PADA

Case Studies, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
25 Mar 2021

Intranasal Immunization: Promises and Challenges

Webinars, Pharmaceutical, Sustainability, Innovation & Insights, Device Innovations, Market Insights, Product Solutions

Read More
19 Mar 2021

Otimização de processos no desenvolvimento de produtos inalatórios orais e nasais.

Webinars, Pharmaceutical, Product Solutions

Read More
27 Jan 2021

COVID 19: Drug Delivery Options to Succeed Sooner

Webinars, Pharmaceutical, Innovation & Insights, Device Innovations, Market Insights, Product Solutions

Read More
1 16 17 18 19 20 25

Request Access

Close

Requesting access to Aptar Pharma discusses intranasal administration for CNS therapeutics.

  • This field is for validation purposes and should be left unchanged.
Back To Top